Qualifying for TIL therapy

Currently, TIL therapy is approved by the US Food and Drug Administration for patients with advanced (metastatic) melanoma. Not all patients with metastatic melanoma automatically qualify for TIL therapy. In addition, physicians assess organ function and performance status to ensure the patient can tolerate the therapy. Social support is another critical factor, as patients need reliable transportation and assistance throughout their treatment journey.

 Eligibility criteria

• >18 years of age with unresectable or metastatic melanoma

• Must have progressed on at least 1 previous systemic therapy, including a PD-L1 antibody, and if they had BRAF V600E mutation–positive disease, a BRAF or BRAF/MEK inhibitor

• At least 1 resectable lesion

• NCCN's Category 2A designation in the NCCN Melanoma Guidelines (v2.2024)

• Physicians will assess organ function and performance status to ensure the patient can tolerate the therapy.

• Social support is another critical factor, as patients need reliable transportation and assistance throughout their treatment journey.

There are clinical trials open to study the use of TIL therapy in other solid tumor cancers.